Cargando…

Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

BACKGROUND: As recommended in the current prescribing information, rituximab infusions in patients with rheumatoid arthritis (RA) take 4.25 hours for the first infusion and 3.25 hours for subsequent infusions, which is a burden on patients and the health care system. We therefore evaluated the safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pritchard, Charles H, Greenwald, Maria W, Kremer, Joel M, Gaylis, Norman B, Rigby, William, Zlotnick, Steve, Chung, Carol, Jaber, Birgit, Reiss, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035685/ https://www.ncbi.nlm.nih.gov/pubmed/24884454 http://dx.doi.org/10.1186/1471-2474-15-177

Ejemplares similares

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry
por: Harrold, Leslie R., et al.
Publicado: (2017)

A rheumatoid factor paradox: inhibition of rituximab effector function
por: Jones, Jonathan D, et al.
Publicado: (2013)

Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme
por: Yamanaka, Hisashi, et al.
Publicado: (2017)

Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice
por: Pappas, Dimitrios A., et al.
Publicado: (2019)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis
por: Emery, Paul, et al.
Publicado: (2011)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

SEVERE ADENOVIRUS PNEUMONIA IN RITUXIMAB INFUSIONS
por: BJORK, SARAH, et al.
Publicado: (2021)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

Real-world Comparative Effectiveness of Tocilizumab Monotherapy vs. Tumor Necrosis Factor Inhibitors with Methotrexate in Patients with Rheumatoid Arthritis
por: Harrold, Leslie R., et al.
Publicado: (2018)

Investigation of $\alpha$-decay rates of $^{221}$Fr, $^{224}$Ra and $^{226}$Ra in different environments.
por: Jeppesen, H B, et al.
Publicado: (2006)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan
por: Yokoyama, Masahiro, et al.
Publicado: (2013)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Rapid Infusion Rituximab for Maintenance Therapy: Is It Feasible?
por: Patel, Jolly, et al.
Publicado: (2013)

Allergic/infusion reactions reported with cetuximab and rituximab
por: Wolf, Ray A, et al.
Publicado: (2015)

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
por: Rivellese, Felice, et al.
Publicado: (2022)

Overview of biotherapy in rheumatoid arthritis (RA)
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion
por: Lamanna, William C, et al.
Publicado: (2017)

Mortality in Rheumatoid Arthritis (RA): factors associated with recording RA on death certificates
por: Molina, Emily, et al.
Publicado: (2015)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Acute Respiratory Distress Syndrome after Rituximab Infusion
por: Montero, Alberto J., et al.
Publicado: (2005)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Secure LoRa Firmware Update with Adaptive Data Rate Techniques †
por: Heeger, Derek, et al.
Publicado: (2021)

Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013)

Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI
por: Peterfy, Charles G, et al.
Publicado: (2012)

Heart rate variability during infusion of dexmedetomidine
por: Imabayashi, T, et al.
Publicado: (2011)

The Variable Rate Intravenous Insulin Infusion Protocol
por: Collard, Benjamin, et al.
Publicado: (2013)

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
por: Tak, Paul P, et al.
Publicado: (2011)

Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data
por: Hawley, Samuel, et al.
Publicado: (2019)

Acute Myocardial Infarction after First Dose of Rituximab Infusion
por: Gogia, Ajay, et al.
Publicado: (2014)

A Case of Coronary Vasospasm after Repeat Rituximab Infusion
por: Ke, Calvin, et al.
Publicado: (2015)

Ultrafast 30‐min infusion of a rituximab biosimilar (Truxima)
por: Pérez‐Persona, Ernesto, et al.
Publicado: (2023)

MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study
por: Peterfy, Charles, et al.
Publicado: (2016)

Anti-Ro/SSA antibodies in rheumatoid arthritis (RA)
por: Franceschini, F, et al.
Publicado: (2003)

Lysozyme and its biological value in rheumatoid arthritis (RA)
por: Smirnow, J, et al.
Publicado: (2001)

Intestinal anaerobic bacteria in early rheumatoid arthritis (RA)
por: Toivanen, P, et al.
Publicado: (2002)

IL2RA is associated with persistence of rheumatoid arthritis
por: van Steenbergen, H.W., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s0lrar3u4anqivifcnuse0653e